Olodanrigan (sodium)

CAT: 0804-HY-13106ASize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-13106ASize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4].
CAS Number
[1316755-17-5]
Product Name Alternative
EMA401 (sodium) ; PD-126055 (sodium)
UNSPSC
12352005
Target
Angiotensin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/olodanrigan-sodium.html
Solubility
10 mM in DMSO
Smiles
O=C([C@H]1N(C(C(C2=CC=CC=C2)C3=CC=CC=C3)=O)CC4=C(C(OCC5=CC=CC=C5)=C(OC)C=C4)C1)O[Na]
Molecular Formula
C32H28NNaO5
Molecular Weight
529.56
References & Citations
[1]Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383 (9929) :1637-47.|[2]Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.|[3]Suguru Koyama, et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
AT2 Receptor

Popular Products